enVVeno Medical Corp (NVNO): who owns it and who trades it
As of Nov 16, 2026, NVNO insiders reported 4 open-market sales worth $4.9K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Francis Duhay (Director), with $4.9K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, NVNO insiders reported $0 of open-market purchases and $4.9K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Francis Duhay | Director | Sale plan | 11 | $11.21 | $123 | Form 4 |
| Jun 11, 2026 | Francis Duhay | Director | Sale plan | 140 | $10.31 | $1.4K | Form 4 |
| Mar 12, 2026 | Francis Duhay | Director | Sale plan | 140 | $11.52 | $1.6K | Form 4 |
| Dec 11, 2025 | Francis Duhay | Director | Sale plan | 4,900 | $0.36 | $1.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Francis Duhay | Director | – | $4.9K | Sep 11, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NVNO short interest
Low short interest. 3.5% of NVNO shares are sold short: about 1 share in 29. Over the last 12 reports the number of shares short went down 66%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 24,103 NVNO shares were sold short, 3.5% of the shares outstanding, up 104.8% from the report before. At the average daily volume of 39,897 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 24,103 | 3.47% | +105% | 39,897 | 1.0 |
| Oct 15, 2026 | 11,771 | 1.72% | -13% | 35,372 | 1.0 |
| Sep 30, 2026 | 13,511 | 1.98% | +44% | 19,666 | 1.0 |
| Sep 15, 2026 | 9,377 | 1.37% | +11% | 38,494 | 1.0 |
| Aug 31, 2026 | 8,442 | 1.24% | -65% | 16,811 | 1.0 |
| Aug 14, 2026 | 24,403 | 3.57% | +33% | 19,456 | 1.2 |
| Jul 31, 2026 | 18,286 | 2.68% | +69% | 19,970 | 1.0 |
| Jul 15, 2026 | 10,839 | 1.65% | +1% | 22,771 | 1.0 |
| Jun 30, 2026 | 10,784 | 1.65% | -27% | 7,873 | 1.4 |
| Jun 15, 2026 | 14,788 | 2.26% | -79% | 7,743 | 1.9 |
| May 29, 2026 | 70,022 | 10.68% | -2% | 11,794 | 5.9 |
| May 15, 2026 | 71,103 | 10.85% | +18% | 11,049 | 6.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
enVVeno Medical company events
enVVeno Medical filed 6 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Jul 14, 2026.
- Jul 14, 2026AnnouncementShared information with investors. Filing
- Apr 29, 2026AnnouncementEnVVeno Medical Corporation announced that the Company received notification from the FDA that it had approved the Company’s IDE application, authorizing the Company to commence a study of a non-surgical replacement venous valve. Filing
- Feb 4, 2026AnnouncementThe Company announced that it regained compliance with the minimum bid price requirement and all other criteria for continued listing on The NASDAQ Stock Market. Filing
- Jan 20, 2026RulesChanged its bylaws or articles. Filing
- Dec 12, 2025VoteReported shareholder vote results. Filing
- Nov 20, 2025RulesChanged its bylaws or articles. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
enVVeno Medical financials
Famous investors that hold NVNO
1 of the 50 well-known investors we track reported holding NVNO in their latest 13F filing. The largest position is Ken Griffin's, worth $130K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 15,314 | $130K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named NVNO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | Thomas A. Satterfield, Jr. | 13G/A | 4.8% |
| Nov 10, 2026 | Thomas A. Satterfield, Jr. | 13G/A | 4.8% |
Questions about enVVeno Medical Corp (NVNO) stock
Are NVNO insiders buying or selling?
In the last 12 months, NVNO insiders reported no open-market purchases and 4 sales worth $4.9K. The latest trade was on Sep 11, 2026. See every trade.
What is the short interest in NVNO?
As of Oct 30, 2026, 24,103 NVNO shares were sold short, 3.5% of the shares outstanding, up 104.8% from the report before. At the average daily volume of 39,897 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold NVNO?
1 of the 50 well-known investors we track reported NVNO in their latest 13F filing, including Ken Griffin. The largest position is worth $130K. See all holders.
Executive pay
enVVeno Medical's chief executive was paid a total of $584K for the year ended Dec 31, 2025, down 50% from $1.2M the year before. In the last 12 months, enVVeno Medical's executives and directors bought no stock on the open market and sold $4.9K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.